Values First Advisors Inc. Lowers Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Values First Advisors Inc. trimmed its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 55.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,740 shares of the company’s stock after selling 21,179 shares during the quarter. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $494,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Polar Capital Holdings Plc raised its position in shares of Mirum Pharmaceuticals by 27.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company’s stock worth $37,130,000 after acquiring an additional 250,000 shares in the last quarter. Raymond James & Associates increased its position in Mirum Pharmaceuticals by 57.1% during the 3rd quarter. Raymond James & Associates now owns 106,207 shares of the company’s stock valued at $3,356,000 after buying an additional 38,619 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Mirum Pharmaceuticals by 210.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company’s stock valued at $7,096,000 after buying an additional 152,287 shares in the last quarter. Rafferty Asset Management LLC increased its position in Mirum Pharmaceuticals by 18.4% during the 3rd quarter. Rafferty Asset Management LLC now owns 137,205 shares of the company’s stock valued at $4,336,000 after buying an additional 21,312 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Mirum Pharmaceuticals by 202.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 114,109 shares of the company’s stock valued at $3,606,000 after buying an additional 76,369 shares in the last quarter.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 1,408 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.03, for a total transaction of $39,466.24. Following the completion of the sale, the chief operating officer now owns 36,485 shares of the company’s stock, valued at $1,022,674.55. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Peter Radovich sold 1,408 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.03, for a total transaction of $39,466.24. Following the completion of the transaction, the chief operating officer now directly owns 36,485 shares in the company, valued at $1,022,674.55. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Lara Longpre sold 1,019 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.04, for a total value of $28,572.76. Following the transaction, the insider now owns 105,254 shares of the company’s stock, valued at $2,951,322.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,202 shares of company stock valued at $359,119. 24.06% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock remained flat at $25.12 during mid-day trading on Thursday. The company’s stock had a trading volume of 424,360 shares, compared to its average volume of 597,991. The company has a fifty day moving average price of $27.46 and a 200-day moving average price of $29.20. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $21.83 and a fifty-two week high of $35.56. The stock has a market capitalization of $1.18 billion, a PE ratio of -6.34 and a beta of 1.16. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The firm had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. JMP Securities boosted their price target on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, March 14th. Raymond James dropped their price target on Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, December 19th. SVB Leerink lowered their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. HC Wainwright upped their target price on Mirum Pharmaceuticals from $45.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $52.11.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.